|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Adenosine#Adverse Reactions]] |
| {{Adenosine}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Adverse Reactions==
| |
| The following reactions were reported with intravenous Adenocard (adenosine injection) used in controlled U.S. clinical trials. The placebo group had less than 1% rate of all of these reactions.
| |
| ===Cardiovascular===
| |
| Facial [[flushing]] (18%),[[headache]] (2%), sweating, [[palpitations]], [[chest pain]], [[hypotension]] (less than 1%).
| |
| ===Respiratory===
| |
| | |
| Shortness of breath/[[dyspnea]] (12%), chest pressure (7%), hyperventilation, head pressure (less than 1%).
| |
| ===Central Nervous System===
| |
| | |
| [[Lightheadedness]] (2%), [[dizziness]], tingling in arms, [[numbness]] (1%), apprehension, [[blurred vision]], burning sensation, heaviness in arms, neck and back pain (less than 1%).
| |
| ===Gastrointestinal===
| |
| | |
| Nausea (3%), metallic taste, tightness in throat, pressure in groin (less than 1%).
| |
| ==Post Marketing Experience (see Warnings)==
| |
| The following adverse events have been reported from marketing experience with Adenocard. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.
| |
| ===Cardiovascular===
| |
| | |
| Prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, atrial fibrillation, and Torsade de Pointes
| |
| ===Respiratory===
| |
| | |
| Bronchospasm
| |
| ===Central Nervous System===
| |
| | |
| Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| [[Category:Antiarrhythmic agents]]
| |